May. 11 at 11:51 PM
$TENX $TENX Extremely bullish setup developing here. TNX-103 isn’t some brand-new untested molecule — levosimendan already has years of international clinical experience and physician familiarity. That dramatically lowers the scientific risk compared to many early-stage biotech names.
The company just completed enrollment in the Phase 3 LEVEL trial ahead of topline data expected in Q3 2026, which is a massive milestone. Institutions clearly recognize the opportunity here — major biotech funds like RTW, BVF, Janus, Vivo, Venrock and T. Rowe Price are involved.
Most importantly, TENX is targeting PH-HFpEF, a huge unmet medical need with very limited treatment options. If TNX-103 shows strong efficacy, this could become one of the most important cardiopulmonary therapies in the space.
The market is finally starting to understand:
* Existing international experience with levosimendan
* Strong KOL support
* Fully enrolled Phase 3 program
* Institutional accumulation
* Large addressable
